Vcanbio Cell & Gene Engineering Corp

Vcanbio Cell & Gene Engineering Corp EBIT per Share

The EBIT per Share of Vcanbio Cell & Gene Engineering Corp (600645.SS) as of Nov 17, 2026 is 0.43 CNY. In the previous year, EBIT per Share was 0.29 CNY — a change of 46.57% (higher).

EBIT per Share

0.43CNY

YoY

46.57%

Last updated:

EBIT per Share of Vcanbio Cell & Gene Engineering Corp is 2025 0.43 CNY. EBIT per Share of Vcanbio Cell & Gene Engineering Corp was 2024 0.29 CNY. It decreases by 46.57% higher compared to the previous year.

The Vcanbio Cell & Gene Engineering Corp EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2019
0.25 CNY
Jan 1, 2020
-0.20 CNY
Jan 1, 2021
0.45 CNY
Jan 1, 2022
0.33 CNY
Jan 1, 2023
0.28 CNY
Jan 1, 2024
0.29 CNY
Jan 1, 2025
0.43 CNY
Jan 1, 2026 (e)
0.54 CNY
The Vcanbio Cell & Gene Engineering Corp EBIT per Share history
YEAREBIT per ShareYoY
est0.54CNY+25.71%
0.43CNY+46.57%
0.29CNY+4.97%
0.28CNY-15.95%
0.33CNY-26.22%
0.45CNY-329.47%
-0.20CNY-178.45%
0.25CNY-4.50%
0.26CNY+77.83%
0.15CNY-35.94%
0.23CNY-64.70%
0.65CNY+303.80%
0.16CNY+1,430.08%
0.01CNY-70.98%
0.04CNY-75.62%
0.15CNY+12.70%
0.13CNY+104.38%
0.06CNY-15.15%
0.08CNY-46.45%
0.14CNY+1,861.03%
0.01CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Vcanbio Cell & Gene Engineering Corp Stock analysis

What does Vcanbio Cell & Gene Engineering Corp do? Vcanbio Cell & Gene Engineering Corp., Ltd. generates revenue through the development and sale of life sciences technology products. The company produces cytokines culture solutions, cosmetics, and detection reagents for domestic markets. Its business segments include cell culture, gene detection and storage, and the production of specialized biological products. The firm's domestic customers primarily purchase these products for research and commercial applications in the life sciences sector. Vcanbio focuses on cell culture and gene detection services, which are integral to its product offerings. The company's cytokines culture solutions are sold to domestic clients in the biotechnology and pharmaceutical industries. Detection reagents are also marketed to domestic laboratories and healthcare providers for diagnostic purposes. The firm leverages its 2,332 full-time employees to support research, development, and production activities. The company's product portfolio includes cosmetics alongside scientific reagents, targeting both consumer and professional markets. Domestic markets remain the primary focus for all sales, with no mention of international operations. Vcanbio's revenue streams are derived from the sale of its core products, which are developed and manufactured in-house. Vcanbio Cell & Gene Engineering Corp is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vcanbio Cell & Gene Engineering Corp stock

EBIT per Share of Vcanbio Cell & Gene Engineering Corp is 0.43 CNY in 2025.

EBIT per Share of Vcanbio Cell & Gene Engineering Corp changed from 0.29 CNY to 0.43 CNY, representing a 46.57% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Vcanbio Cell & Gene Engineering Corp since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Vcanbio Cell & Gene Engineering Corp

All Key Metrics — Vcanbio Cell & Gene Engineering Corp